Vext Science (VEXT) AI Stock Analysis

• Market Cap: C$59.44M
• Dividend Yield: N/A
• Average Volume (3M): 40.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.41
• Revenue Growth: 43.56%
• EPS Growth: -349.41%
• Country: CA
• Employees: 173
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 180,409,180
• 10 Day Avg. Volume: 23,955
• 30 Day Avg. Volume: 40,052
• PEG Ratio: <0.01
• Price to Book (P/B): 0.38
• Price to Sales (P/S): 0.81
• P/FCF Ratio: 15.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.04
• Revenue Forecast (FY): C$75.90M

• Rating: 51 Neutral
• Price Target: C$0.50 ▲(78.57% Upside)

Vext Science's overall stock score reflects a mixed outlook. Strong revenue growth and cash flow improvements are offset by profitability challenges and a negative P/E ratio. Technical indicators suggest weak momentum, and while the earnings call was positive, market challenges remain significant.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market expansion and product adoption, particularly in Ohio, supporting long-term business sustainability.

Cash Flow Improvements

Consistent positive cash flow enhances financial stability and allows for reinvestment in growth opportunities, ensuring long-term viability.

Cultivation Yield Improvements

Improved yields suggest enhanced operational efficiency, reducing costs and potentially increasing margins, contributing to long-term profitability.

Negative Factors

Profitability Challenges

Negative profitability metrics indicate operational inefficiencies, which can hinder long-term financial health and shareholder value creation.

Arizona Market Challenges

Pricing pressures in Arizona can compress margins and impact revenue, posing a risk to sustained growth in a key market.

Permitting Delays in Ohio

Delays in store openings can affect revenue growth and market presence, potentially slowing down strategic expansion plans.

Vext Science Business Overview & Revenue Model

Company Description

Vext Science (VEXT) is a diversified cannabis company operating in the legal cannabis market, primarily focused on the production and sale of high-quality cannabis products. The company operates in multiple sectors, including cultivation, processing, and retail, providing a range of products such as flower, oils, edibles, and other cannabis-infused goods. Vext Science aims to deliver innovative and effective solutions to consumers while adhering to regulatory standards and promoting responsible use.

How the Company Makes Money

Vext Science generates revenue through several key streams, including the sale of its cannabis products directly to consumers via its retail outlets and through wholesale distribution to other dispensaries. The company capitalizes on its cultivation and processing capabilities to ensure a steady supply of high-quality cannabis, which helps maintain competitive pricing and product availability. Additionally, Vext Science may explore strategic partnerships with other businesses in the cannabis sector, enhancing its distribution channels and product offerings. Factors contributing to its earnings include market demand for cannabis products, effective branding and marketing strategies, and compliance with evolving regulations in the cannabis industry.

Vext Science Financial Statement Overview

Summary

Vext Science shows mixed financial performance. Revenue growth and cash flow metrics are positive, with significant free cash flow growth and improved cash generation. However, profitability remains a concern due to negative net income and EBIT margins. The balance sheet is stable, but the negative return on equity indicates challenges in generating shareholder value.

Income Statement

Vext Science shows a mixed performance in its income statement. The company has experienced a positive revenue growth rate of 12.71% in the TTM, indicating a recovery from previous declines. However, profitability metrics such as the net profit margin and EBIT margin are negative, reflecting ongoing operational challenges. The gross profit margin has improved to 30.02% in the TTM, but the negative EBIT and net income highlight profitability issues.

Balance Sheet

The balance sheet of Vext Science presents a moderate financial position. The debt-to-equity ratio is relatively stable at 0.50, suggesting a balanced approach to leveraging. However, the return on equity is negative in the TTM, indicating inefficiencies in generating returns for shareholders. The equity ratio remains healthy, showing that a significant portion of the company's assets is financed by equity.

Cash Flow

Vext Science's cash flow statement reveals some positive trends. The free cash flow has grown significantly by 113.47% in the TTM, and the operating cash flow to net income ratio is 0.58, indicating improved cash generation capabilities. The free cash flow to net income ratio is also strong at 0.78, suggesting that the company is effectively converting its earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	44.15M	36.00M	34.81M	35.41M	37.24M	25.19M
Gross Profit	13.25M	8.98M	12.04M	23.10M	18.69M	11.20M
EBITDA	6.27M	-2.02M	16.77M	15.03M	12.80M	5.52M
Net Income	-16.52M	-22.44M	4.40M	10.92M	4.99M	2.13M
Balance Sheet
Total Assets	132.88M	136.97M	149.56M	120.52M	83.70M	55.45M
Cash, Cash Equivalents and Short-Term Investments	4.55M	4.62M	8.72M	5.93M	6.47M	1.75M
Total Debt	35.62M	39.52M	38.60M	38.15M	14.10M	11.49M
Total Liabilities	61.84M	61.23M	54.58M	48.60M	24.31M	19.14M
Stockholders Equity	71.04M	75.74M	94.98M	71.92M	59.39M	36.31M
Cash Flow
Free Cash Flow	8.65M	1.82M	1.69M	-2.94M	-7.10M	-964.90K
Operating Cash Flow	11.03M	3.29M	4.42M	5.92M	11.68M	3.10M
Investing Cash Flow	-4.99M	-5.44M	-4.82M	-30.31M	-27.10M	-12.90M
Financing Cash Flow	-4.88M	-1.95M	3.19M	23.86M	20.14M	4.26M

Vext Science Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VEXT, the sentiment is Negative. The current price of 0.28 is above the 20-day moving average (MA) of 0.26, below the 50-day MA of 0.30, and above the 200-day MA of 0.20, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 42.77 is Neutral, neither overbought nor oversold. The STOCH value of 19.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:VEXT.

Vext Science Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DB	63 Neutral	$77.85M	5.19	21.77%	―	15.11%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VEXT	51 Neutral	C$59.44M	―	-21.73%	―	43.56%	-349.41%
ROMJ	48 Neutral	$33.25M	183.33	7.78%	―	28.55%	―
GWAY	44 Neutral	C$19.83M	―	-15.75%	―	26.75%	61.79%
CXXI	43 Neutral	C$82.83M	―	-9.90%	―	23.29%	33.65%
LABS	41 Neutral	$27.35M	―	-19.10%	―	18.06%	34.58%

Vext Science Corporate Events

Vext Science Reports Strong Q3 2025 Revenue Growth

Vext Science, Inc. is a U.S.-based cannabis operator with operations in Arizona and Ohio, known for its vertical integration from cultivation to retail and its Vapen™ brand of THC products.

Vext Science Sees 41% Revenue Growth in Q3 2025 Amid Ohio Expansion

Vext Science reported a 41% year-over-year increase in revenue for Q3 2025, reaching $12.7 million, driven by expanded operations in Ohio and strong performance in Arizona. The company achieved a year-to-date operating cash flow of $8.5 million, a significant improvement from the previous year’s negative cash flow. Vext is on track to expand its Ohio retail locations to eight by 2026, positioning itself to capitalize on the state’s growing cannabis market. The company’s disciplined operations and strategic expansion are expected to drive sustainable growth and long-term value for shareholders.

The most recent analyst rating on (TSE:VEXT) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.

Vext Science Achieves 41% Revenue Growth in Q3 2025

Vext Science reported a 41% year-over-year increase in revenue for Q3 2025, reaching $12.7 million, driven by expanded retail operations in Ohio and consistent performance in Arizona. The company achieved a year-to-date operating cash flow of $8.5 million, a significant improvement from the previous year. Vext’s strategic focus on Ohio’s adult-use market is evident as it strengthens its retail presence with plans to reach the state dispensary license cap by 2026. This expansion positions Vext to capture sustained growth and leverage its vertically-integrated platform for long-term shareholder value.

The most recent analyst rating on (TSE:VEXT) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.

Vext Science to Release Q3 2025 Financial Results on November 20

Vext Science, Inc. announced it will release its Q3 2025 financial results on November 20, 2025, followed by a conference call and webcast to discuss the results. This announcement is significant as it provides stakeholders with insights into the company’s financial health and strategic direction in the competitive cannabis industry.

The most recent analyst rating on (TSE:VEXT) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.

Vext Science Expands Ohio Footprint with Portsmouth Dispensary Acquisition

Vext Science, Inc. has secured state approval for the ownership transfer of the Herbal Wellness Center dispensary in Portsmouth, Ohio, marking its fifth fully consolidated dispensary in the state. This move is part of Vext’s strategic expansion in Ohio, aiming to reach the state’s eight-store cap by late 2025 or early 2026. The Portsmouth location, which includes a drive-thru, enhances Vext’s retail footprint and supports its vertically integrated platform, contributing to margin expansion and cash flow generation. With ongoing construction and permitting for three additional locations, Vext is poised to operate the state maximum of eight dispensaries, reinforcing its position in the growing Ohio cannabis market.

The most recent analyst rating on (TSE:VEXT) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.

Vext Science Earnings Call: Ohio Growth Shines

The recent earnings call for Vext Science highlighted a mixed sentiment, with strong performance in Ohio driving significant revenue growth and improved EBITDA margins. However, challenges in the Arizona market and a decline in wholesale sales were noted as hurdles. Overall, the positive growth in Ohio and operational improvements slightly outweighed the issues faced in Arizona.

Vext Science Reports Record Q2 2025 Revenue

Vext Science, Inc. is a U.S.-based cannabis operator with vertical operations in Arizona and Ohio, specializing in cultivation, manufacturing, and retail of cannabis products, including the Vapen™ brand.